PCI Biotech Holding ASA (PCIB.OL)
NOK 1.41
(-3.42%)
NOK 1.41
(-3.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5 Million NOK | -17.62% |
| 2022 | 6.07 Million NOK | -72.6% |
| 2021 | 22.18 Million NOK | 11.61% |
| 2020 | 19.87 Million NOK | -26.93% |
| 2019 | 27.2 Million NOK | 59.07% |
| 2018 | 17.1 Million NOK | 3.06% |
| 2017 | 16.59 Million NOK | 78.2% |
| 2016 | 9.31 Million NOK | -23.14% |
| 2015 | 12.11 Million NOK | 7.52% |
| 2014 | 11.26 Million NOK | 20.64% |
| 2013 | 9.34 Million NOK | 9.95% |
| 2012 | 8.49 Million NOK | 11.31% |
| 2011 | 7.63 Million NOK | -16.3% |
| 2010 | 9.11 Million NOK | 41.32% |
| 2009 | 6.45 Million NOK | 22.31% |
| 2008 | 5.27 Million NOK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.5 Million NOK | 0.0% |
| 2024 Q1 | 5.5 Million NOK | 9.99% |
| 2023 Q1 | 5.45 Million NOK | -10.28% |
| 2023 Q3 | 5 Million NOK | -10.78% |
| 2023 Q2 | 5.61 Million NOK | 2.9% |
| 2023 FY | 5 Million NOK | -17.62% |
| 2023 Q4 | 5 Million NOK | 0.0% |
| 2022 Q2 | 17.31 Million NOK | -15.98% |
| 2022 Q4 | 6.07 Million NOK | -41.85% |
| 2022 Q3 | 10.45 Million NOK | -39.63% |
| 2022 Q1 | 20.6 Million NOK | -7.11% |
| 2022 FY | 6.07 Million NOK | -72.6% |
| 2021 Q2 | 17.92 Million NOK | 2.0% |
| 2021 Q1 | 17.56 Million NOK | -11.62% |
| 2021 Q4 | 22.18 Million NOK | 19.63% |
| 2021 Q3 | 18.54 Million NOK | 3.49% |
| 2021 FY | 22.18 Million NOK | 11.61% |
| 2020 Q4 | 19.87 Million NOK | -17.55% |
| 2020 Q1 | 20.47 Million NOK | -24.74% |
| 2020 Q2 | 24.69 Million NOK | 20.63% |
| 2020 Q3 | 24.11 Million NOK | -2.38% |
| 2020 FY | 19.87 Million NOK | -26.93% |
| 2019 Q1 | 22.12 Million NOK | 29.35% |
| 2019 Q2 | 30.18 Million NOK | 36.43% |
| 2019 Q3 | 29.38 Million NOK | -2.65% |
| 2019 Q4 | 27.2 Million NOK | -7.41% |
| 2019 FY | 27.2 Million NOK | 59.07% |
| 2018 Q2 | 15.44 Million NOK | -18.25% |
| 2018 Q1 | 18.88 Million NOK | 13.82% |
| 2018 Q4 | 17.1 Million NOK | 5.36% |
| 2018 FY | 17.1 Million NOK | 3.06% |
| 2018 Q3 | 16.23 Million NOK | 5.12% |
| 2017 Q3 | 9.8 Million NOK | 18.13% |
| 2017 Q2 | 8.3 Million NOK | -17.78% |
| 2017 Q1 | 10.09 Million NOK | 8.42% |
| 2017 FY | 16.59 Million NOK | 78.2% |
| 2017 Q4 | 16.59 Million NOK | 69.22% |
| 2016 Q2 | 11.36 Million NOK | 10.29% |
| 2016 Q1 | 10.3 Million NOK | -14.98% |
| 2016 Q3 | 10.86 Million NOK | -4.36% |
| 2016 Q4 | 9.31 Million NOK | -14.29% |
| 2016 FY | 9.31 Million NOK | -23.14% |
| 2015 Q1 | 11.17 Million NOK | -0.81% |
| 2015 FY | 12.11 Million NOK | 7.52% |
| 2015 Q3 | 9.21 Million NOK | 7.24% |
| 2015 Q2 | 8.59 Million NOK | -23.15% |
| 2015 Q4 | 12.11 Million NOK | 31.51% |
| 2014 FY | 11.26 Million NOK | 20.64% |
| 2014 Q4 | 11.26 Million NOK | 36.05% |
| 2014 Q2 | 8.09 Million NOK | -2.72% |
| 2014 Q3 | 8.28 Million NOK | 2.31% |
| 2014 Q1 | 8.32 Million NOK | -10.91% |
| 2013 Q2 | 5.99 Million NOK | -25.96% |
| 2013 Q3 | 6.97 Million NOK | 16.36% |
| 2013 Q4 | 9.34 Million NOK | 33.85% |
| 2013 FY | 9.34 Million NOK | 9.95% |
| 2013 Q1 | 8.1 Million NOK | -4.65% |
| 2012 Q1 | 8.31 Million NOK | 8.94% |
| 2012 Q2 | 7.76 Million NOK | -6.62% |
| 2012 FY | 8.49 Million NOK | 11.31% |
| 2012 Q3 | 7.25 Million NOK | -6.5% |
| 2012 Q4 | 8.49 Million NOK | 17.03% |
| 2011 FY | 7.63 Million NOK | -16.3% |
| 2011 Q1 | 7.78 Million NOK | -14.62% |
| 2011 Q3 | 7.5 Million NOK | -4.98% |
| 2011 Q2 | 7.89 Million NOK | 1.45% |
| 2011 Q4 | 7.63 Million NOK | 1.69% |
| 2010 Q3 | 7.37 Million NOK | -26.61% |
| 2010 Q2 | 10.04 Million NOK | 0.0% |
| 2010 FY | 9.11 Million NOK | 41.32% |
| 2010 Q4 | 9.11 Million NOK | 23.7% |
| 2009 FY | 6.45 Million NOK | 22.31% |
| 2009 Q4 | 6.45 Million NOK | 0.0% |
| 2008 FY | 5.27 Million NOK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arctic Bioscience AS | 41.69 Million NOK | 87.989% |
| Aqua Bio Technology ASA | 15.72 Million NOK | 68.149% |
| ArcticZymes Technologies ASA | 30.02 Million NOK | 83.321% |
| BerGenBio ASA | 46.85 Million NOK | 89.313% |
| Hofseth BioCare ASA | 348.97 Million NOK | 98.565% |
| Thor Medical ASA | 58.91 Million NOK | 91.499% |
| Ultimovacs ASA | 69.64 Million NOK | 92.81% |